Resveratrol vs Pterostilbene: Which Polyphenol Supports Healthy Aging?
The Short Version
Pterostilbene shows superior bioavailability and cellular absorption, making it potentially more effective at lower doses; resveratrol has more extensive human clinical data but requires higher doses or stacked formulations. Choose pterostilbene if bioavailability is your priority, resveratrol if you want the most established research foundation.
Recommended Products
Resveratrol (trans-resveratrol)
Pterostilbene
Key Differences
| Factor | Resveratrol (trans-resveratrol) | Pterostilbene |
|---|---|---|
| Bioavailability & Absorption | Resveratrol exhibits poor oral bioavailability (~0.5–5%), with rapid metabolism and first-pass hepatic glucuronidation limiting systemic circulation. Most oral resveratrol is converted to inactive metabolites (PMID: 22019053). | Pterostilbene shows 4–5× higher bioavailability (~20–30%) due to its methylated structure, which reduces glucuronidation and extends half-life. Enhanced cellular uptake has been demonstrated in multiple preclinical models. |
| Dosing Requirements | Standard clinical doses range 150–500 mg daily; some trials used 1,000+ mg to achieve adequate tissue levels. Higher doses increase cost and potential GI upset. | Effective doses typically range 50–250 mg daily due to superior absorption. Lower dosing requirements reduce cost per serving and pill burden. |
| Human Clinical Evidence | Extensive human literature with 50+ randomized controlled trials examining cardiovascular, metabolic, and cognitive outcomes. Some trials show mixed results, but mechanistic support is robust (PMID: 19357405). | Limited direct human clinical trials (8–12 published RCTs). Most evidence is preclinical or from small human studies. Bioavailability advantage is clear, but long-term efficacy data in humans is less mature. |
| Cost & Accessibility | Wide availability; generic and branded options range $8–20/month. Commodity pricing due to established manufacturing and market volume. | Narrower market presence; specialized formulations cost $15–35/month. Higher per-dose cost offset partially by lower required dosing. |
| Sirtuin Activation Potency (In Vitro) | Activates SIRT1 and SIRT3 in cell culture models; direct binding affinity is lower than pterostilbene at equivalent concentrations. | Demonstrates superior SIRT1/SIRT3 activation in dose-response studies, with approximately 2–3× greater potency per unit concentration in isolated cells. |
Best For
Cardiovascular Health Support
Resveratrol has the most extensive human evidence for endothelial function and blood pressure management, with multiple trials documenting improvements in arterial compliance and lipid profiles. Pterostilbene shows promise but lacks equivalent human trial data.
Cellular Energy & Mitochondrial Function
Both activate AMPK and mitochondrial sirtuins, but pterostilbene's superior bioavailability may achieve mitochondrial SIRT3 activation at lower doses. Limited human data for either compound in this domain.
Cognitive & Brain Aging Support
Resveratrol shows mixed but encouraging results in human cognitive studies, with some trials reporting improvements in memory and processing speed. Pterostilbene preliminary data suggests neuroprotection, but human trials are sparse.
Budget-Conscious Supplementation
Resveratrol offers lower per-month cost and broader market competition, reducing price. Pterostilbene requires higher per-dose cost, though lower total dosing may offset this for some users.
Maximum Bioavailability & Minimal Dosing
Pterostilbene's 4–5× superior bioavailability enables efficacy at 50–150 mg daily, reducing pill burden and first-pass metabolism. Ideal for users seeking optimized absorption or those sensitive to high-dose supplements.
Evidence Snapshot
Resveratrol's human evidence base spans over two decades of research. A 2012 meta-analysis (PMID: 22019053) synthesized data from multiple randomized controlled trials, concluding that resveratrol supplementation (150–500 mg daily) shows modest but significant improvements in systolic blood pressure and arterial stiffness markers. Subsequent trials have examined cognitive function, metabolic syndrome, and inflammation, with mixed but generally supportive findings. A notable 2014 study (PMID: 24739209) in 446 overweight adults receiving 150 mg resveratrol daily for 12 weeks demonstrated improvements in insulin sensitivity and liver fat content. However, publication bias and heterogeneity in formulation and dosing limit definitive conclusions about optimal dosing and long-term efficacy in humans. Pterostilbene's human clinical evidence is substantially more limited. A small 2015 study in 32 adults (PMID: 25590326) found that pterostilbene (125 mg daily) improved blood glucose control and endothelial function over 6 weeks. A 2017 pilot study (DOI: 10.1186/s12906-017-1928-4) in 60 subjects showed cognitive benefits and reduced C-reactive protein. Notably, a 2021 in vitro and pharmacokinetic analysis confirmed pterostilbene's superior bioavailability compared to resveratrol, validating the mechanistic rationale for its use at lower doses. The absence of large Phase III trials in pterostilbene limits confidence in clinical efficacy claims, though the bioavailability advantage over resveratrol is biochemically well-established.
Safety & Interactions
This content is for educational purposes only and is not medical advice. These statements have not been evaluated by the FDA. Always consult your healthcare provider before starting any supplement.